PURPOSE: Maternal medication use during pregnancy is explored extensively, as it may cause birth defects. This study aimed to evaluate the validity of recorded medication use in the Medical Birth Registry of Norway (MBRN). METHODS: This study was based on the nationwide population-based registries, the MBRN and the Norwegian Prescription Database (NorPD). These registries were linked using a unique 11-digit identification number. The sensitivity, specificity and positive predictive value (PPV) of recorded medication use in MBRN were computed using data from NorPD as the reference. RESULTS: Among the 163,678 pregnancies included in our study, the sensitivity for total drug use during pregnancy was calculated to be 32% and PPV was 82%. When we looked at the use of medication during the whole pregnancy, the sensitivities of drug registration for the main groups in the Anatomical Therapeutic Chemical (ATC)-classification varied from 50% (ATC group H) to 2% (ATC group S). CONCLUSION: The medication use recorded in MBRN is poor compared with prescribed medicines registered in NorPD. There was a substantial difference between the different ATC codes regarding the sensitivity of MBRN in the registration of medication use during pregnancy.
PURPOSE: Maternal medication use during pregnancy is explored extensively, as it may cause birth defects. This study aimed to evaluate the validity of recorded medication use in the Medical Birth Registry of Norway (MBRN). METHODS: This study was based on the nationwide population-based registries, the MBRN and the Norwegian Prescription Database (NorPD). These registries were linked using a unique 11-digit identification number. The sensitivity, specificity and positive predictive value (PPV) of recorded medication use in MBRN were computed using data from NorPD as the reference. RESULTS: Among the 163,678 pregnancies included in our study, the sensitivity for total drug use during pregnancy was calculated to be 32% and PPV was 82%. When we looked at the use of medication during the whole pregnancy, the sensitivities of drug registration for the main groups in the Anatomical Therapeutic Chemical (ATC)-classification varied from 50% (ATC group H) to 2% (ATC group S). CONCLUSION: The medication use recorded in MBRN is poor compared with prescribed medicines registered in NorPD. There was a substantial difference between the different ATC codes regarding the sensitivity of MBRN in the registration of medication use during pregnancy.
Authors: Jani van der Hoven; Elizabeth Allen; Annibale Cois; Renee de Waal; Gary Maartens; Landon Myer; Thokozile Malaba; Hlengiwe Madlala; Dorothy Nyemba; Florence Phelanyane; Andrew Boulle; Ushma Mehta; Emma Kalk Journal: BMC Pregnancy Childbirth Date: 2022-06-03 Impact factor: 3.105
Authors: Linda de Jonge; Ester Garne; Rosa Gini; Susan E Jordan; Kari Klungsoyr; Maria Loane; Amanda J Neville; Anna Pierini; Aurora Puccini; Daniel S Thayer; David Tucker; Anne Vinkel Hansen; Marian K Bakker Journal: Drug Saf Date: 2015-11 Impact factor: 5.606
Authors: Rachel A Charlton; Anna Pierini; Kari Klungsøyr; Amanda J Neville; Susan Jordan; Lolkje T W de Jong-van den Berg; Daniel Thayer; H Jens Bos; Aurora Puccini; Anne V Hansen; Rosa Gini; Anders Engeland; Anne-Marie Nybo Andersen; Helen Dolk; Ester Garne Journal: BMJ Open Date: 2016-01-19 Impact factor: 2.692
Authors: Rachel A Charlton; Kari Klungsøyr; Amanda J Neville; Sue Jordan; Anna Pierini; Lolkje T W de Jong-van den Berg; H Jens Bos; Aurora Puccini; Anders Engeland; Rosa Gini; Gareth Davies; Daniel Thayer; Anne V Hansen; Margery Morgan; Hao Wang; Anita McGrogan; Anne-Marie Nybo Andersen; Helen Dolk; Ester Garne Journal: PLoS One Date: 2016-05-18 Impact factor: 3.240